YOLFTbeta
68

Hunan Nucien Pharmaceutical Co Ltd

688189 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

6.13CNY-0.08 (-1.29%)

Price History

Full chart

Market Stats

Previous Close6.21
Open6.18
Day Range6.10 – 6.25
52-Week Range5.47 – 11.39
Volume551.63K
Market Cap1.76B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.49
Dividend Yield0.00%
Beta0.24
50-Day Avg6.62
200-Day Avg7.66

About

Hunan Nucien Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the research and development, production, and sale of chemical drugs in China. The company also focuses on the research, development, production, and sales of antiviral drugs, including influenza and infectious disease prevention and treatment drugs, as well as medicines for anti-influenza, malignant tumors, cardiovascular, antibiotics, antipyretics, pain relief, diabetes, analgesic, cerebrovascular, respiratory, and other pharmaceutical fields. Hunan Nucien Pharmaceutical Co., Ltd. was founded in 2006 and is based in Guangzhou, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Liang Li
  • Employees277
  • HeadquartersBuilding 1-2, Guangzhou, China, 510100, China
  • Websitehttps://www.nucien.com

Leadership

  • Mr. Liang LiDeputy GM & CFO · b. 1976
  • Mr. Shi JianDeputy General Manager · b. 1977
  • Mr. Shukao LiuDeputy General Manager · b. 1981
  • Mr. Xuan LiSecretary of the Board · b. 1984
  • Mr. Shi Xi ZhangVice Chairman & GM · b. 1974
  • Xiaoning ChenAccounting Supervisor

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue278.20M347.52M700.52M1.01B1.03B743.66M698.83M655.38M251.72M141.93M
Growth (%)-+24.92%+101.58%+44.78%+1.47%-27.74%-6.03%-6.22%-61.59%-43.62%
Cost of Revenue110.38M100.33M101.01M115.49M104.88M95.75M99.32M109.21M119.56M97.22M
Gross Profit167.81M247.19M599.51M898.73M924.26M647.91M599.51M546.17M132.17M44.71M
Gross Margin60.32%71.13%85.58%88.61%89.81%87.12%85.79%83.34%52.51%31.50%
Operating Expense125.71M196.01M521.85M764.04M763.00M730.48M534.93M504.55M208.85M122.96M
Operating Income42.10M51.19M77.66M134.69M161.26M-82.57M64.57M41.62M-76.69M-78.24M
Operating Margin15.13%14.73%11.09%13.28%15.67%-11.10%9.24%6.35%-30.46%-55.13%
EBITDA-84.36M118.43M163.48M189.81M-164.86M-2.51M31.38M-333.13M-93.23M
EBITDA Margin-24.28%16.91%16.12%18.44%-22.17%-0.36%4.79%-132.34%-65.69%
Net Income14.61M27.15M53.53M91.47M127.97M-161.88M-77.46M-21.27M-346.51M-136.90M
Net Income Margin5.25%7.81%7.64%9.02%12.43%-21.77%-11.08%-3.25%-137.65%-96.46%
R&D7.86M17.48M45.26M71.76M94.04M78.03M58.16M74.86M48.81M35.36M
R&D as % of Total Revenue2.83%5.03%6.46%7.08%9.14%10.49%8.32%11.42%19.39%24.91%
Interest Expense0014.33M15.53M13.38M15.92M22.03M15.25M5.40M3.58M
Interest Expense % of Total Revenue0.00%0.00%2.05%1.53%1.30%2.14%3.15%2.33%2.15%2.52%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets614.53M602.53M696.05M818.72M2.09B2.13B1.95B1.71B1.22B809.47M
Total Liabilities443.35M400.14M431.23M461.45M466.87M736.89M658.24M433.80M344.13M97.06M
Total Equity153.63M180.78M234.30M332.56M1.60B1.39B1.31B1.29B936.59M783.55M
Cash109.01M74.93M125.02M154.60M299.35M730.67M713.47M665.76M490.27M301.52M
Net Debt-206.33M177.33M185.82M46.05M-----

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow75.35M70.72M64.41M32.56M-290.84M-63.11M-160.09M215.23M1.39M114.57M
Capital Expenditure38.49M46.49M21.50M12.80M27.50M113.59M41.01M31.49M58.43M79.80M
Free Cash Flow-24.24M42.91M19.76M-318.34M-176.70M-201.10M183.74M-57.03M34.77M
Dividends Paid50.97M13.50M14.22M15.46M13.51M56.31M16.36M15.82M5.23M2.71M
FCF to OCF-34.27%66.62%60.69%109.46%279.98%125.61%85.37%-4092.77%30.35%
Dividend Paid to FCF-55.70%33.14%78.24%-4.24%-31.87%-8.14%8.61%-9.16%7.79%

Earnings

Report DateMar 6, 2020Apr 28, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate0.00-------------
EPS Actual0.870.190.080.080.230.090.070.03-0.790.040.02-0.01-0.340.05
Surprise--------------
Timing--------------

Key Statistics & Ratios

Market Cap1.76B
Enterprise Value1.49B
Trailing P/E0.00
Forward P/E0.00
Price / Sales12.91
Price / Book2.28
EPS-0.49
Book Value2.89
Revenue (TTM)136.13M
Gross Profit (TTM)21.59M
EBITDA-62.95M
Profit Margin-98.48%
Operating Margin-79.74%
Return on Equity-19.01%
Return on Assets-6.11%
Shares Outstanding272.83M
Shares Float147.53M
Beta0.24
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20211×
0.15Aug 17, 2021

Stock Splits

  • Jun 13, 20237:5
  • Jul 22, 20227:5